DengYue Medicine
LightNews LightNews
banner
dengyuemedicine.bsky.social
DengYue Medicine
@dengyuemedicine.bsky.social
2 followers 1 following 19 posts
DengYue Medicine exports 30,000+ Chinese medicines globally, including oncology, hematology, and orphan drugs. We ensure safety, efficacy, and international certification compliance.
Posts Replies Media Videos
dengyuemedicine.bsky.social
China’s NMPA Grants Conditional Approval for Taletrectinib Adipate Capsules

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #TaletrectinibAdipate #Dabole #ROS1Positive #NSCLC #LungCancer #TargetedTherapy #Oncology #BaoyuanBiopharma
November 13, 2025 at 6:46 AM
dengyuemedicine.bsky.social
China NMPA Approves Donanemab Injection for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#Donanemab #EliLilly #AlzheimersDisease #NMPA #DrugApproval #MonoclonalAntibody #Neuroscience #ChinaPharma
November 12, 2025 at 6:56 AM
dengyuemedicine.bsky.social
China’s NMPA Approves Sentagliptin Phosphate Tablets for Market Launch

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaDrugApproval #NMPA #SentagliptinPhosphate #Type2Diabetes #InnovativeMedicine #Shengjievi #Biopharma #Suzhou
November 11, 2025 at 7:58 AM
dengyuemedicine.bsky.social
China NMPA Approves Secituzumab Tirumotecan for Injection

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #SecituzumabTirumotecan #ADC #TROP2 #TripleNegativeBreastCancer #KelunBiotech #Jiatailai
November 10, 2025 at 3:17 AM
dengyuemedicine.bsky.social
China NMPA Grants Conditional Approval for Garsorasib Tablets

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #Garsorasib #NSCLC #KRASG12C #InnovativeDrug #ChiataiTianqing #LungCancer
November 7, 2025 at 8:45 AM
dengyuemedicine.bsky.social
China NMPA Approves Pradefovir Mesylate Tablets for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#NMPA #ChinaDrugApproval #PradefovirMesylate #Xinshumu #HepatitisB #InnovativeDrug #XiAnGelanXintong #PharmaceuticalNews
November 6, 2025 at 6:57 AM
dengyuemedicine.bsky.social
Approval of Ongericimab Injection by China NMPA

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#NMPAApproval #OngericimabInjection #JunshiBiosciences #PCSK9Inhibitor #CholesterolTreatment #Hyperlipidemia #InnovativeMedicine #ChinaBiopharma
November 5, 2025 at 7:13 AM
dengyuemedicine.bsky.social
China NMPA Conditionally Approves Iparomlimab and Tuvonralimab Injection for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#NMPA #Iparomlimab #Tuvonralimab #Qibeian #CervicalCancer #Immunotherapy #BispecificAntibody #QiluPharmaceutical #ChineseInnovativeDrugs #Oncology
November 4, 2025 at 9:19 AM
dengyuemedicine.bsky.social
China NMPA Approves Ebronucimab Injection for Hypercholesterolemia Treatment

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#Ebronucimab #PCSK9Inhibitor #CholesterolTreatment #NMPAApproval #ChineseBiologics #Hypercholesterolemia #CardiovascularHealth #KangrongDongfang
November 3, 2025 at 9:46 AM
dengyuemedicine.bsky.social
China NMPA Approves Spuqibai Monoclonal Antibody Injection for Market

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#KeymedBio #StapokibartInjection #InnovativeDrugs #AtopicDermatitis #IL4RAntibody #BiopharmaChina #BiotechInnovation #ChinesePharmaceuticals #DrugApproval #Biologics
November 1, 2025 at 7:53 AM
dengyuemedicine.bsky.social
China NMPA Approves Funakizumab Injection for Moderate-to-Severe Plaque Psoriasis

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#NMPA #DrugApproval #MonoclonalAntibody #IL17A #Psoriasis #BiopharmaChina #InnovativeDrug
October 31, 2025 at 6:15 AM
dengyuemedicine.bsky.social
China NMPA Approves Xeligekimab Injection for the Treatment of Plaque Psoriasis

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#DrugApproval #Psoriasis #IL17A #Biologics #ChinaPharma #DengYueMedicine
October 30, 2025 at 6:32 AM
dengyuemedicine.bsky.social
China NMPA Conditionally Approves Golixitinib Capsules for Market

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaPharma #OncologyInnovation #Golixitinib #PTCL #Dizal #NMPA #DengYueMedicine #PharmaceuticalExports #JAKInhibitor #ChineseInnovativeDrugs
October 29, 2025 at 2:45 AM
dengyuemedicine.bsky.social
China NMPA Approves Icodec Insulin Injection(Awiqli) for Market Launch

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#InsulinIcodec
#Awiqli
#NovoNordisk
#NMPAApproval
#ChinaDrugAdministration
#Type2Diabetes
#LongActingInsulin
#DiabetesTreatment
#PharmaceuticalNews
#2024DrugApprovals
October 28, 2025 at 6:20 AM
dengyuemedicine.bsky.social
National Medical Products Administration (NMPA) has approved the marketing of Cogriptin Tablets.

📩 info@dengyuemed.com
🔗 dengyuemed.com

#Cogriptin #Beichangping #HisunPharma #Type2Diabetes #DPP4Inhibitor #GLP1 #GIP #NMPA #ChinaPharma #InnovativeDrug #DiabetesTreatment #BloodGlucoseControl
October 27, 2025 at 7:21 AM
dengyuemedicine.bsky.social
China’s Pharma Exports: A New Global Chapter in Healthcare Trade

📩 info@dengyuemed.com
🔗https://dengyuemed.com/

#PharmaceuticalExports #ChinaPharma #GlobalHealthcare #Innovation #Trade #HongKong #LifeSciences #PharmaIndustry #HealthcareInnovation #DengYueMedicine
October 24, 2025 at 8:20 AM
dengyuemedicine.bsky.social
$850 Billion Pharma Boom: Why DengYue Leads the Next Wave #dengyuemed

📩 info@dengyuemed.com
🔗https://dengyuemed.com/

#DengYueMed #PharmaTrade #GlobalHealth #ChinaPharma #BeltAndRoad #HealthcareInnovation #PharmaceuticalExports
October 18, 2025 at 6:46 AM
dengyuemedicine.bsky.social
China’s Innovative Drugs Go Global | DengYueMed Connecting Chinese Pharma to the World

📩 info@dengyuemed.com
🔗https://dengyuemed.com/

#ChinaPharma #InnovativeDrugs #GlobalHealth #PharmaExport #DengYueMed #Biopharma #MadeInChina #HealthcareInnovation #HongKong #PharmaLogistics
October 17, 2025 at 6:34 AM
dengyuemedicine.bsky.social
From Hong Kong to the World: How DengYue Medicine Bridges China’s Innovative Pharma

📩 info@dengyuemed.com
🔗https://dengyuemed.com/

#ChinaPharma #GlobalHealth #DengYueMedicine #HongKongPharma #InnovativeDrugs #PharmaExport #ClinicalTrials #OncologyCare #ChinaInnovation #PharmaLogistics
October 16, 2025 at 8:10 AM